Effects of a high-fat meal on the relative oral bioavailability of piperaquine

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 6, 2005, Pages 2407-2411

  Sim, Ing Kye ^a   Davis, Timothy M E ^a   Ilett, Kenneth F ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Western Australian Centre for Pathology and Medical Research   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PIPERAQUINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; FATIGUE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEADACHE; HEARING DISORDER; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; LIPID DIET; LIPID SOLUBILITY; MALE; NAUSEA; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; POSTPRANDIAL STATE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; VISUAL DISORDER; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANTIMALARIALS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DIETARY FATS; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; QUINOLINES;

EID: 19544380591     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.6.2407-2411.2005     Document Type: Article

References (25)

1. Anonymous. 2001. Guidance for industry: statistical approaches to establishing bioequivalence. Appendix D, p. 32-33. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, Md.
2. Anonymous. 2002. Guidance for industry. Food-effect in bioavailability and fed bioequivalence studies, p. 1-9. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, Md.
3. Anonymous. 2004. Piperaquine. American Chemical Society, Columbus, Ohio. [Online.] http://www.cas.org/SCIFINDER/SCHOLAR/.
4. Chen, L. 1991. Recent studies on antimalarial efficacy of piperaquine and hydroxypiperaquine. Chinese Med. J. 104:161-163.
5. Chen, L., Z. R. Dai, Y. L. Qian, Z. M. Ma, F. C. Guo, Z. H. Liao, D. D. Fu, D. Q. Ma, and X. J. Pang. 1989. Observation on the efficacy of combined use of some new antimalarials for the treatment of falciparum malaria in Hainan Province. Chinese J. Parasitol. Parasitic Dis. 7:81-84.
6. Chen, L., F. Y. Qu, and Y. C. Zhou. 1982. Field observations on the antimalarial piperaquine. Chinese Med. J. 95:281-286.
7. 14C- piperaquine in mice. Pharm. Ind. 8:19-23.
8. Crevoisier, C., J. Handschin, J. Barre, D. Roumenov, and C. Kleinbloesem. 1997. Food increases the bioavailability of mefloquine. Eur. J. Clin. Pharmacol. 53:135-139.
9. Davis, T. M. 1997. Antimalarial drugs and glucose metabolism. Br. J. Clin. Pharmacol. 44:1-7.
10. Davis, T. M. E., T.-Y. Hung, I.-K. Sim, H. A. Karunajeewa, and K. F. Ilett. 2005. Piperaquine; a resurgent antimalarial drug. Drugs 65:75-87.
11. Gibaldi, M. 1984. Gastrointestinal absorption: biologic considerations, p. 29-43. In Biopharmaceutics and clinical pharmacokinetics. Lea & Febiger, Philadelphia, Pa.
12. Guo, X. B. 1993. Randomized comparison on the treatment of falciparum malaria with dihydroartemisinin and piperaquine. Zhonghua Yi Xue Za Zhi 73:602-604.
13. Guo, X. B., and L. C. Fu. 1989. Comparative study of artemisinin suppositories and piperaquine phosphate in the treatment of falciparum malaria. Zhong Xi Yi Jie He Za Zhi 9:473-475.
14. Hien, T. T., C. Dolecek, P. P. Mai, N. T. Dung, N. T. Truong, L. H. Thai, D. T. H. An, T. T. Thanh, K. Stepniewska, N. J. White, and J. Farrar. 2004. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 363:18-22.
15. Huang, J. Z., X. H. Lan, and W. Z. Xu. 1985. Sensitivity of Plasmodium falciparum to piperaquine in Baoting County, Hainan Island. Chinese J. Parasitol. Parasitic Dis. 3:276-277.
16. Hung, T. Y., T. M. E. Davis, and K. F. Ilett. 2003. Measurement of piperaquine in plasma by liquid chromatography with ultraviolet absorbance detection. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 791:93-101.
17. Hung, T. Y., T. M. E. Davis, K. F. Ilett, H. Karunajeewa, S. Hewitt, M. B. Denis, C. Lim, and D. Socheat. 2004. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol. 57:253-262.
18. Karbwang, J., and K. Na-Bangchang. 1994. Clinical application of mefloquine pharmacokinetics in the treatment of Plasmodium falciparum malaria. Fund. Clin. Pharmacol. 8:491-502.
19. Karunajeewa, H. A., A. Kemiki, M. Alpers, K. Lorry, K. T. Batty, K. F. Ilett, and T. M. E. Davis. 2003. Safety and therapeutic efficacy of artesunate suppositories for treatment of malaria in children in Papua New Guinea. Pediatr. Infect. Dis. 22:251-256.
20. Lan, C. X., X. Lin, Z. S. Huang, Y. S. Chen, and R. N. Guo. 1989. In vivo sensitivity of Plasmodium falciparum to piperaquine phosphate assayed in Linshui and Baisha counties, Hainan province. Chinese J. Parasitol. Parasitic Dis. 7:163-165.
21. Milton, K. A., G. Edwards, S. A. Ward, M. L. Orme, and A. M. Breckenridge. 1989. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br. J. Clin. Pharmacol. 28:71-77.
22. Mohanlal, N., and R. R. Holman. 2004. A standardized triglyceride and carbohydrate challenge: the oral triglyceride tolerance test. Diabetes Care 27:89-94.
23. Rolan, P. E., A. J. Mercer, B. C. Weatherley, T. Holdich, H. Meire, R. W. Peck, G. Ridout, and J. Posner. 1994. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br. J. Clin. Pharmacol. 37:13-20.
24. Schmidt, L. E., and K. Dalhoff. 2002. Food-drug interactions. Drugs 62:1481-1502.
25. Sheng, N., W. Jiang, and H. L. Tang. 1981. Pre-clinical toxicological study of new antimalarial agents: II. Piperaquine phosphate and its compound "Preventive No. 3." Ti Erh Chun i Ta Hsueh Hsueh Pao 1:40-46.